Sector News

Monsanto bid may mean Bayer will cut pharma R&D spending

June 1, 2016
Energy & Chemical Value Chain

The proposed $62bn merger with agrochemical firm Monsanto would jeopardise Bayer’s pharmaceutical business, according to a BMI Research analyst.

> Read the full article on the in-Pharma Technologist website

By Dan Stanton

Source: in-Pharma Technologist

comments closed

Related News

May 17, 2024

Italian Treasury divests 2.8% stake in Eni for €1.4bn

Energy & Chemical Value Chain

Italy’s Treasury has sold a 2.8% stake in oil and gas company Eni, raising approximately €1.4bn. Despite this reduction, the Italian Government will own a third of Eni, with a combined stake of more than 30% held between the Treasury and state lender Cassa Depositi e Prestiti, which owns another 28.5% stake.

May 17, 2024

Umicore announces CEO succession

Energy & Chemical Value Chain

Umicore announces the appointment of Bart Sap as Chief Executive Officer, effective May 16th. He will succeed Mathias Miedreich who has decided to step down, in mutual agreement with the Supervisory Board. Bart Sap joined Umicore in 2004 and has been the Executive Vice President Catalysis since March 2021.

May 17, 2024

MOL Inaugurates €1.3 Billion Polyols Complex in Hungary

Energy & Chemical Value Chain

Hungarian energy and petrochemicals group MOL has inaugurated its €1.3 billion polyol complex in Tiszaújváros, Hungary, with a capacity of around 200,000 t/y of polyol, a widely used plastic raw material. According to MOL, the commissioning is a significant milestone, as it is the only company in Hungary and Central and Eastern Europe that covers the entire value chain from crude oil processing to polyol production.

How can we help you?

We're easy to reach